Canada: Federal Court Of Appeal Provides Important Guidance For Determining Jurisdiction Of The PMPRB

Last Updated: July 12 2019
Article by CyberLex Blog, Fiona Legere, Rebecca Crane and Edwin Mok

On June 28, 2019, in the Federal Court of Appeal's decision in Attorney General of Canada v Galderma Canada Inc., 2019 FCA 196, the Court confirmed that the Patented Medicines Price Review Board ("PMPRB" or the "Board") acted unreasonably in the manner in which it made its determination that Canadian Patent No. 2,478,237 (the "237 Patent") pertained to the drug Differin. The Court therefore set aside the Board's decision, but given the particular factual circumstances, returned the matter to the Board for redetermination. This decision provides important guidance for the determination of whether an invention pertains to a medicine, which is a key factor in deciding whether the PMPRB has jurisdiction over a medicine under the Patent Act (the "Act").

1. Background to the Decision

Under the Act, the PMPRB has jurisdiction to, among other things, demand certain pricing information regarding patented medicine from patentees in respect of "an invention pertaining to a medicine." The Act further provides that "an invention pertains to a medicine if the invention is intended or capable of being used for medicine or for the preparation or production of medicine."

Galderma Canada Inc. ("Galderma") markets Differin, a product used for the treatment of acne, containing the active ingredient, adapalene at a concentration of 0.1% by weight. Galderma had identified two patents – Patent Nos. 1,266,646 (the "646 Patent") and 1,312,075 (the "075 Patent") – as pertaining to Differin. In keeping with its obligations under the Act, Galderma provided the PMPRB with sales and financial information related to Differin until the expiration of those patents. The later-expiring of the two, the 075 Patent, expired on December 29, 2009.

In January 2016, the PMPRB brought an application seeking an order that Galderma provide sales and financial information related to Differin for a period after December 29, 2009, on the basis that a patent other than the 646 and 075 Patents – namely, the 237 Patent – pertained to Differin. The 237 Patent had been identified by Galderma as pertaining to the product Differin XP, which has the active ingredient of adapalene at a concentration of 0.3% by weight, but not to Differin, which contains adapalene at a concentration of 0.1% by weight. The 237 Patent describes and claims the use of compositions comprising 0.3% by weight of adapalene in the treatment of dermatological disorders.

On December 19, 2016, the Board determined that the 237 Patent pertained to the Differin, rejecting Galderma's argument that the 237 Patent related only to Differin XP, and ordered that Galderma file the prescribed information regarding Differin with the PMPRB. Upon judicial review, the Federal Court quashed the Board's decision, holding that the Board was unreasonable in its conclusion that the 237 Patent pertained to Differin. The Board appealed to the Federal Court of Appeal.

2. The Federal Court of Appeal's Decision

After dealing with the applicable standard of review, the Court addressed the three issues on appeal:

A. Did the Board act unreasonably in limiting its review of the 237 Patent to selected portions of the patent?
B. What is the invention of the 237 Patent?
C. Does the invention of the 237 Patent pertain to Differin?

On the first issue, the Court found that the Board had acted unreasonably in referring only to the abstract and an introductory paragraph of the 237 Patent in making its determination, while ignoring critical parts of the patent, including the claims. The Court also confirmed, however, that while the Board had to "read the patent as a whole," it was not required to go "beyond the face of the patent" to construe the claims of the 237 Patent.

On the second issue, the Court agreed with the court below that the Board had failed to make a determination of what the invention of the 237 Patent was. Instead, the Board had limited its inquiry to whether the 237 Patent was limited exclusively to the 0.3% concentration of adapalene, and found that it was not so limited based on an improper selective reading of the patent.

The Court then stated that because the Board had wrongly limited its inquiry, the matter should be referred back to the Board to complete its mandate. However, upon review of the 237 Patent, the Court held that there is only one reasonable interpretation as to the nature of the invention of the 237 Patent: "a pharmaceutical composition having a concentration of 0.3% adapalene to be used in the treatment of dermatological conditions with an inflammatory or proliferative component, such as common acne." In so finding, the Court noted that the 237 Patent repeatedly discusses compositions comprising 0.3% by weight of adapalene and the advantages thereof, and also that each claim of the patent recites compositions comprising no less than 0.3% by weight of adapalene.

On the third issue, the Court addressed the principles applied by the Board in determining whether an invention "pertains to a medicine" under the Act. In particular, the Court noted the Board had relied on the language of "rational connection or nexus" and "merest slender thread" between the invention and the medicine, taken from the decision in ICN Pharmaceuticals, Inc. v. Canada (Staff of the Patented Medicine Prices Review Board) (1996), [1997] 1 F.C. 32, 138 D.L.R. (4th) 7 (FCA). The Court stated that "[t]he expression 'merest slender thread' is a metaphor designed to express the idea that the connection may be tenuous," but that it must be understood in context of the actual statutory text, which uses the language of "pertaining to" or "pertains to." The Court then expressed concern that the Board appeared at times in its decision to be substituting a "rational connection" and "merest slender thread" test for the test set out in the statute.

In the end, the Court sent the question of whether the invention of the 237 Patent pertains to Differin back to the Board, in order to apply the understanding of the invention of the 237 Patent as articulated by the Court. The Court noted that if the Board's decision had rested solely on the premise that the 237 Patent was not exclusively related to 0.3% adapalene, then the court below was correct in quashing the Board's decision. But the Board, the Court observed, did make reference to other factors that if considered could have influenced the decision, including evidence related to the product monograph, comparisons and studies in the patent itself, and evidence from clinicians. The Board never addressed how these factors would affect the determination of whether the 237 Patent pertains to Differin, and so the Court decided that the appropriate remedy was to return the matter to the Board for redetermination – but in light of the Court's articulation of the invention of the 237 Patent.

3. Implications of the Decision

While the outcome of the Board's redetermination on whether the 237 Patent pertains to Differin will no doubt be tracked by practitioners in this space, it is the Federal Court of Appeal's findings and comments regarding the errors made by the Board that will have wider immediate implications.

First, the Court confirmed that in determining what is the "invention" for purposes of section 79 of the Act, the Board must consider the patent as a whole, including the claims, and not rely only on selective portions. At the same time, however, the Board is not to construe the patent and the claims as a court would. To discharge its mandate, the Court stated, what the Board needs is "a sufficient understanding of the invention of a patent so as to be able to make a reasonable determination as to whether the invention pertains to a medicine."

Second, with respect to the determination of whether an invention "pertains to" a medicine, the Court's decision serves as a caution that the Board must not conflate the proper statutory test with language such as "rational connection" and "merest slender thread" that has developed in the jurisprudence. Expressions like "merest slender thread," the Court noted, are metaphors – potentially helpful, but not a substitute for the words of Parliament. As the Court made clear: "There is only one test, namely the test set out at subsection 79(2) of the Act."

To view the original article click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions